Matthew Kennedy-Martin1, Bernhard Slaap2,3, Michael Herdman4, Mandy van Reenen3, Tessa Kennedy-Martin5, Wolfgang Greiner6, Jan Busschbach2, Kristina S Boye7. 1. Kennedy Martin Health Outcomes Ltd, Suite 404, The Dock Hub, Wilbury Villas, Hove, BN3 6AH, UK. matt@kmho.co.uk. 2. Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, The Netherlands. 3. EuroQol Research Foundation, Rotterdam, The Netherlands. 4. Office of Health Economics (OHE), London, UK. 5. Kennedy Martin Health Outcomes Ltd, Suite 404, The Dock Hub, Wilbury Villas, Hove, BN3 6AH, UK. 6. Department of Health Economics at the School of Public Health, Bielefeld University, Bielefeld, Germany. 7. Eli Lilly and Company, Indianapolis, IN, USA.
Abstract
BACKGROUND: Several multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment (HTA) agencies regarding the choice of MAUIs. METHODS: A list was compiled of HTA agencies that provide or refer to published official pharmacoeconomic (PE) guidelines for pricing, reimbursement or market access. The guidelines were reviewed for recommendations on the indirect calculation of utilities and categorized as: a preference for a specific MAUI; providing no MAUI preference, but providing examples of suitable MAUIs and/or recommending the use of national value sets; and recommending CUA, but not providing examples of MAUIs. RESULTS: Thirty-four PE guidelines were included for review. MAUIs named for use in CUA: EQ-5D (n = 29 guidelines), the SF-6D (n = 11), HUI (n = 10), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). EQ-5D was a preferred MAUI in 15 guidelines. Alongside the EQ-5D, the HUI was a preferred MAUI in one guideline, with DALY disability weights mentioned in another. Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). Of those that did not specify a particular MAUI, 12 preferred calculating utilities using national preference weights. CONCLUSIONS: The EQ-5D, HUI, and SF-6D were the three MAUIs most frequently mentioned in guidelines. The most commonly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI for use in CUA in HTA.
BACKGROUND: Several multi-attribute utility instruments (MAUIs) are available from which utilities can be derived for use in cost-utility analysis (CUA). This study provides a review of recommendations from national health technology assessment (HTA) agencies regarding the choice of MAUIs. METHODS: A list was compiled of HTA agencies that provide or refer to published official pharmacoeconomic (PE) guidelines for pricing, reimbursement or market access. The guidelines were reviewed for recommendations on the indirect calculation of utilities and categorized as: a preference for a specific MAUI; providing no MAUI preference, but providing examples of suitable MAUIs and/or recommending the use of national value sets; and recommending CUA, but not providing examples of MAUIs. RESULTS: Thirty-four PE guidelines were included for review. MAUIs named for use in CUA: EQ-5D (n = 29 guidelines), the SF-6D (n = 11), HUI (n = 10), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). EQ-5D was a preferred MAUI in 15 guidelines. Alongside the EQ-5D, the HUI was a preferred MAUI in one guideline, with DALY disability weights mentioned in another. Fourteen guidelines expressed no preference for a specific MAUI, but provided examples: EQ-5D (n = 14), SF-6D (n = 11), HUI (n = 9), QWB (n = 3), AQoL (n = 2), CHU9D (n = 1). Of those that did not specify a particular MAUI, 12 preferred calculating utilities using national preference weights. CONCLUSIONS: The EQ-5D, HUI, and SF-6D were the three MAUIs most frequently mentioned in guidelines. The most commonly cited MAUI (in 85% of PE guidelines) was EQ-5D, either as a preferred MAUI or as an example of a suitable MAUI for use in CUA in HTA.
Authors: E Haydn Walters; Andrew J Palmer; Ingrid A Cox; Barbara de Graaff; Hasnat Ahmed; Julie Campbell; Petr Otahal; Tamera J Corte; Ian Glaspole; Yuben Moodley; Nicole Goh; Sacha Macansh Journal: Qual Life Res Date: 2021-05-17 Impact factor: 4.147
Authors: Ingrid A Cox; Julie Campbell; Barbara de Graaff; Petr Otahal; Tamera J Corte; Yuben Moodley; Peter Hopkins; Sacha Macansh; E Haydn Walters; Andrew J Palmer Journal: Qual Life Res Date: 2022-08-04 Impact factor: 3.440
Authors: Wei Liao; Xiaotian Liu; Ning Kang; Yu Song; Yinghao Yuchi; Ze Hu; Jian Hou; Chongjian Wang; Yuqian Li Journal: Qual Life Res Date: 2022-08-16 Impact factor: 3.440
Authors: N Devlin; T Pan; S Kreimeier; J Verstraete; E Stolk; K Rand; M Herdman Journal: Health Qual Life Outcomes Date: 2022-07-06 Impact factor: 3.077
Authors: Tianxin Pan; Brendan Mulhern; Rosalie Viney; Richard Norman; An Tran-Duy; Janel Hanmer; Nancy Devlin Journal: Qual Life Res Date: 2021-06-28 Impact factor: 4.147